Some evidence indicates that MOG content is strongly associated with MS, which modulates anti-myelin immune reactions in both relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) patients [212]. This evidence concerns the gene MOG and secondary progressive multiple sclerosis.